论文部分内容阅读
目的探讨孟鲁司特联合舒利迭对中重度慢性阻塞性肺病(COPD)患者肺功能的影响,为COPD的治疗提供方案。方法将96例中重度COPD患者随机分为对照组、联合用药组,对照组在常规治疗的基础上予舒利迭,联合用药组在对照组治疗的基础上再加用孟鲁司特,疗程8周,比较两组治疗前后第1秒用力呼气容积(FEV1)、FEV1占预计值的百分比(FEV1%预计值)、FEV1/用力肺活量(FEV1/FVC)及动脉血氧分压(PaO2)及二氧化碳分压(PaCO2)的变化。结果两组治疗前各指标之间的差异均无统计学意义(P>0.05)。治疗后,对照组的FEV1、FEV1%预计值、FEV1/FVC分别为(1.43±0.38)L、71.26%±15.28%、75.42%±11.27%,联合用药组分别为(1.71±0.47)L、79.52%±16.83%、83.57%±11.32%,均明显高于对照组,差异均有统计学意义(P<0.05,P<0.01)。对照组治疗后PaO2、PaCO2分别为(71.35±7.21)、(48.69±5.23)mmHg,联合用药组为(78.16±7.47)、(46.32±5.42)mmHg,联合用药组PaO2明显高于对照组,而PaCO2则明显低于对照组,差异均有统计学意义(P<0.01,P<0.05)。结论孟鲁司特联合舒利迭能更好地改善COPD患者的肺功能,安全性高,疗效确切。
Objective To investigate the effect of montelukast and seretide on pulmonary function in patients with moderate-severe chronic obstructive pulmonary disease (COPD) and provide a plan for the treatment of COPD. Methods Ninety-six patients with moderate-to-severe COPD were randomly divided into control group, combination group and control group on the basis of routine treatment with seretide, combined with the control group on the basis of treatment plus montelukast, treatment (FEV1), predicted FEV1 (FEV1% predicted), FEV1 / FVC and PaO2 were compared between the two groups before and after treatment for 8 weeks. And partial pressure of carbon dioxide (PaCO2) changes. Results There was no significant difference between the two groups before treatment (P> 0.05). After treatment, FEV1, FEV1% of the control group and FEV1 / FVC were (1.43 ± 0.38) L, 71.26% ± 15.28% and 75.42% ± 11.27% respectively in the control group and (1.71 ± 0.47) L and 79.52 % ± 16.83% and 83.57% ± 11.32% respectively, which were significantly higher than those in the control group (P <0.05, P <0.01). PaO2 and PaCO2 in the control group were (71.35 ± 7.21) and (48.69 ± 5.23) mmHg respectively, and the combined group was (78.16 ± 7.47) and (46.32 ± 5.42) mmHg, while the PaO2 in the combination group was significantly higher than that in the control group PaCO2 was significantly lower than the control group, the difference was statistically significant (P <0.01, P <0.05). Conclusion Montelukast combined with seretide can better improve lung function in patients with COPD, high safety and curative effect.